GCTK vs TNDM

GlucoTrack, Inc.

(GCTK) offers the better valuation at 0. 0x trailing P/E, making it the more compelling value choice. Analysts rate Tandem Diabetes Care, Inc. (TNDM) a "Buy" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Tandem Diabetes Care, Inc.

(TNDM) delivered a total return of -78. 0%, compared to -100. 0% for GlucoTrack, Inc. (GCTK). Over 10 years, the gap is even starker: TNDM returned -75. 4% versus GCTK's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), GlucoTrack, Inc.

(GCTK) is the lower-risk stock at 1. 37β versus Tandem Diabetes Care, Inc. 's 1. 45β — meaning TNDM is approximately 6% more volatile than GCTK relative to the S&P 500.

On earnings-per-share growth, the picture is similar: GlucoTrack, Inc.

grew EPS 258. 6% year-over-year, compared to -106. 8% for Tandem Diabetes Care, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

GlucoTrack, Inc.

(GCTK) is the more profitable company, earning 0. 0% net margin versus -20. 2% for Tandem Diabetes Care, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GCTK leads at 0. 0% versus -7. 7% for TNDM. At the gross margin level — before operating expenses — TNDM leads at 52. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, GlucoTrack, Inc.

(GCTK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (GCTK: -100. 0%, TNDM: -75. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GCTK is a small-cap deep-value stock; TNDM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.